Our vision & Aim
Slow Down Disease Progression (5 years)
Access to Early Diagnostics and Effective Therapy
Decrease of the Annual Incidence Rate of Dementia (50%)
-
- AnalyzingComprehensive PathologicalCause and Mechanism
-
Phase 1 2020~2022
Exploring novel therapeutic targets
Building platforms for dementia
Implementing a registration system for academic and industrial scientist
-
- Developing Predictive Diagnostic Technology
-
Phase 2 2023~2025
Identifying therapeutic targets
Exploring biomarkers for diagnosis of dementia
Developing prevention program for dementia
-
- Developing New Treatments and Preventive Program
-
Phase 3 2026~2028
Completing IND filing for disease-modifying drug candidates
Commercializing early diagnosis kit for dementia
Implementing dementia prevention programs
Stepwise performance indicators and goals
| Sections |
Phase 1
(2020–2022) |
Phase 2
(2023–2025) |
Phase 3
(2026–2028) |
| Identification of the cause and pathological mechanisms of dementia |
- Initiate discovery of novel targets that passed proof of concept disease relevance
- Publications of 5 papers in top rated journals
|
- Discovery and validation of novel targets that passed proof of concept disease relevance
- Discovery of one novel target for dementia protection
- Publications of 16 papers in top rated journals
|
- Clinical application of one novel target for diagnostic or therapeutics development
- Discovery of novel targets for dementia protection
- Publications of 12 papers in top rated journals
|
| Development of predictive and diagnostic technology |
- Establishment of a dementia prediction platform based on multiple biological signals
- Re-assessment of dementia diagnosis guidelines
- Establishment of TRR registration system (Total ≥ 20 hospitals, registering information of 1,000 applicants)
- Development of dementia Research Information Integration and Connection System (DPK)
|
- Validation of diagnostic marker in preclinical study
- Regulatory approval of 3 Dementia imaging technology
- Establishment of a dementia prediction platform using multiple biological signals
- Improvement and certification of new dementia diagnosis guidelines
- Managemnet of TRR registration system (Total ≥ 20 hospitals, retaining minimum 1,000 applicants)
- Launching Dementia Research Information Integration System (DPK)
|
- Discovery and validation of 2 novel biomarker for dementia diagnosis
- Validation of a diagnostic marker in preclinical study
- Regulatory approval of 4 dementia imaging techmology
- Improvement and certification of a new medical technology
- Management of TRR registration system (Total ≥ 20 hospitals, retaining 1,000 applicants)
- Management of Dementia Research Information Integration System (DPK)
|
| Development of therapeutic technology and prevention program for dementia |
Therapeutic development : IND submission to evaluate a drug candidate in a phase 1 study
|
Therapeutic development : IND submission for a phase 1 study (up to 1)
IND submission for phase 2 (up to 2)
IND submission for Drug delivery technology (1) *
Prevention program : Standardization of Korean Dementia Prevention Program
|
Therapeutic development : IND submission for a phase 1 study (up to 1)
IND submission for phase 2 (up to 3)
IND submission for phase 3 (up to 1)
IND submission for Drug delivery technology (2) *
Prevention program : Advancement of Korean Dementia Prevention Program
|
* regulatory authorization application submission
Goals
Final and Detailed Goals
| Final Goal |
Overcoming dementia and reducing the socioeconomic burden of the people through identifying the cause, early prediction, diagnosis, prevention of dementia, and development of therapeutic techniques. |
| Detailed Goals(Focused Field) |
Identification of the cause and mechanism of dementia Pathogenesis |
Accelerate the process of early diagnosis and treatment by identifying the cause and mechanism of dementia |
| Development of predictive and diagnostic technologies for dementia |
Development of low-cost, low-invasive, high-precision dementia early diagnosis method with high accuracy and accessibility |
| Development of prevention and treatment techniques for dementia |
Development of treatment and prevention technology through diversification of targets, drugs, and treatment method |
Stepwise performance indicators and goals
-
- Phase 1(2020–2022)
-
- Novel target discovery for treatment/diagnosis
- Establishment of dementia prediction platform
- Establishment of research registration system between basic and clinical science
-
- Phase 2(2023–2025)
-
- Clinical trial linkage for above novel treatment targets, IND for clinical Phase 1 and Phase
- Discovery of dementia diagnosis biomarker
- Development of dementia prevention program
-
- Phase 3(2026–2028)
-
- IND for clinical Phase 3above treatments
- Commercialization of early diagnosis for dementia
- Distribution of dementia prevention programs
| Sections |
Phase 1
(2020–2022) |
Phase 2
(2023–2025) |
Phase 3
(2026–2028) |
| Identification of the cause and mechanism of dementia Pathogenesis |
- Discovery of at least one novel target for clinical trials(BRL 5 or higher)
- Publications of 5 papers in top 10% rated journals (or 10 top 20%, 5 patent registrations)
|
- Discovery of at least one novel target for clinical trials (BRL 5 or higher)
- Discovery of at least one novel target for dementia protection (BRL 5 or higher)
- Publications of 16 papers in top 10% rated journals (or 32 top 20 %, 16 patent registrations)
|
- Discovery of at least one novel target for clinical trials (BRL 5 or higher)
- Discovery of at least one novel target for dementia protection (BRL 5 or higher)
- Publications of 12 papers in top 10% rated journals (or 24 top 20% , 12 patent registrations)
|
| Development of predictive and diagnostic technologies for dementia |
- Establishment of a dementia prediction platform based on multiple biological signals (BRL 5~6 or higher)
- Improvement in dementia diagnosis guidelines (1 new medical technology certification
- Establishment of TRR registration system (20 or more hospitals, 1,000 applicants for clinical trials registration)
- Development of Dementia Research Information Integration and Connection System (DPK)
|
- Discovery of at least one novel biomarker for dementia diagnosis (BRL 6 or higher)
- Discovery of at least one preclinical diagnosis method or early dementia
- 3 Dementia imaging technology (radiation medication, contrast medium, target ligand, brain imaging SW, etc.) *
- Establishment of a Dementia prediction platform based on multiple biological signals (BRL 5~6 or higher)
- Improvement in dementia diagnosis guidelines (1 new medical technology certification)
- Management of TRR registration system (20 or more hospitals, 1,000 applicants for clinical trials maintenance)
- Development of Dementia Research Information Integration and Connection System (DPK)
|
- Discovery of at least two Novel biomarkers for dementia diagnosis (BRL 6 or higher)
- 1 Preclinical diagnosis method for early dementia
- 4 Dementia imaging technology (radiation medication, contrast medium, target ligand, brain imaging SW, etc.) *
- Improvement in dementia diagnosis guidelines (1 new medical technology certification)
- Management of TRR registration system (20 or more hospitals, 1,000 applicants for clinical trials)
- Management of Dementia Research Information Integration and Connection System (DPK)
|
| Development of prevention and treatment techniques for dementia |
- 1 IND for clinical Phase 1
|
- 1 IND for clinical phase 1
- 2 IND for clinical phase 2
- 1 Drug delivery technology*
- 1 Development and Standardization of Korean Dementia Prevention Program
|
- 1 IND for clinical phase 1
- 3 IND for clinical phase 2
- 1 IND for clinical phase 3
- 2 Drug delivery technology*
- 1 Advancement of Korean Dementia Prevention Program
|
* regulatory authorization application submission